Drug Insights

Synapse Simplified: How to Find Carbamazepine Information

28 March 2024
2 min read

Carbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body. By virtue of this distinct mechanism of action, it is a valuable pharmacological agent in treating a plethora of disorders, such as bipolar I disorder, partial epilepsies, bipolar disorder, schizophrenia, epilepsy, and trigeminal neuralgia. It was initially synthesized and developed by the pharmaceutical company Novartis, and received its first regulatory approval in the month of March in the year 1965. The efficacy and safety of Carbamazepine in controlling seizures and mood swings associated with bipolar disorder is well-established. Furthermore, its analgesic properties in relieving neuropathic pain in trigeminal neuralgia have been extensively documented. Click on the image below to begin the exploration journey of Carbamazepine through the Synapse database!

图形用户界面, 文本, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Ultomiris Approved by US to Treat Adults with NMOSD
Latest Hotspot
3 min read
Ultomiris Approved by US to Treat Adults with NMOSD
28 March 2024
Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).
Read →
2023 FDA-Approved GPCR-Targeted New Drugs Roundup
Drug Highlight
11 min read
2023 FDA-Approved GPCR-Targeted New Drugs Roundup
28 March 2024
This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.
Read →
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
Latest Hotspot
3 min read
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
27 March 2024
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).
Read →
OKYO Pharma's OK-101 Excels in Phase 2 Trial with Significant Dry Eye Relief
Latest Hotspot
3 min read
OKYO Pharma's OK-101 Excels in Phase 2 Trial with Significant Dry Eye Relief
27 March 2024
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.